283 related articles for article (PubMed ID: 25605246)
1. NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect.
Etani T; Suzuki T; Naiki T; Naiki-Ito A; Ando R; Iida K; Kawai N; Tozawa K; Miyata N; Kohri K; Takahashi S
Oncotarget; 2015 Feb; 6(5):2865-78. PubMed ID: 25605246
[TBL] [Abstract][Full Text] [Related]
2. NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy.
Etani T; Naiki T; Naiki-Ito A; Suzuki T; Iida K; Nozaki S; Kato H; Nagayasu Y; Suzuki S; Kawai N; Yasui T; Takahashi S
J Clin Med; 2019 Mar; 8(4):. PubMed ID: 30935141
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
4. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
[TBL] [Abstract][Full Text] [Related]
5. Selective lysine-specific demethylase 1 inhibitor, NCL1, could cause testicular toxicity via the regulation of apoptosis.
Nozaki S; Naiki T; Naiki-Ito A; Iwatsuki S; Takeda T; Etani T; Nagai T; Iida K; Kato H; Suzuki T; Takahashi S; Umemoto Y; Yasui T
Andrology; 2020 Nov; 8(6):1895-1906. PubMed ID: 32598553
[TBL] [Abstract][Full Text] [Related]
6. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
[TBL] [Abstract][Full Text] [Related]
7. Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells.
Liu S; Lu W; Li S; Li S; Liu J; Xing Y; Zhang S; Zhou JZ; Xing H; Xu Y; Rao Q; Deng C; Wang M; Wang J
Oncotarget; 2017 May; 8(19):31901-31914. PubMed ID: 28404874
[TBL] [Abstract][Full Text] [Related]
8. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R
Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
10. Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells.
Hoshino I; Akutsu Y; Murakami K; Akanuma N; Isozaki Y; Maruyama T; Toyozumi T; Matsumoto Y; Suito H; Takahashi M; Sekino N; Komatsu A; Suzuki T; Matsubara H
Ann Surg Oncol; 2016 Jan; 23(1):312-20. PubMed ID: 25791791
[TBL] [Abstract][Full Text] [Related]
11. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.
Sehrawat A; Gao L; Wang Y; Bankhead A; McWeeney SK; King CJ; Schwartzman J; Urrutia J; Bisson WH; Coleman DJ; Joshi SK; Kim DH; Sampson DA; Weinmann S; Kallakury BVS; Berry DL; Haque R; Van Den Eeden SK; Sharma S; Bearss J; Beer TM; Thomas GV; Heiser LM; Alumkal JJ
Proc Natl Acad Sci U S A; 2018 May; 115(18):E4179-E4188. PubMed ID: 29581250
[TBL] [Abstract][Full Text] [Related]
12. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
[TBL] [Abstract][Full Text] [Related]
14. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
[TBL] [Abstract][Full Text] [Related]
15. The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy.
Liu H; Wei J; Sang N; Zhong X; Zhou X; Yang X; Zhang J; Zuo Z; Zhou Y; Yang S; Du J; Zhao Y
Med Oncol; 2021 Sep; 38(10):124. PubMed ID: 34491469
[TBL] [Abstract][Full Text] [Related]
16. A Rhodium(III)-Based Inhibitor of Lysine-Specific Histone Demethylase 1 as an Epigenetic Modulator in Prostate Cancer Cells.
Yang C; Wang W; Liang JX; Li G; Vellaisamy K; Wong CY; Ma DL; Leung CH
J Med Chem; 2017 Mar; 60(6):2597-2603. PubMed ID: 28219005
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.
Li X; Li T; Chen D; Zhang P; Song Y; Zhu H; Xiao Y; Xing Y
Oncol Rep; 2016 Jan; 35(1):584-92. PubMed ID: 26534764
[TBL] [Abstract][Full Text] [Related]
18. ACSL4 promotes prostate cancer growth, invasion and hormonal resistance.
Wu X; Deng F; Li Y; Daniels G; Du X; Ren Q; Wang J; Wang LH; Yang Y; Zhang V; Zhang D; Ye F; Melamed J; Monaco ME; Lee P
Oncotarget; 2015 Dec; 6(42):44849-63. PubMed ID: 26636648
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
[TBL] [Abstract][Full Text] [Related]
20. Tanshinone IIA inhibits human prostate cancer cells growth by induction of endoplasmic reticulum stress in vitro and in vivo.
Chiu SC; Huang SY; Chen SP; Su CC; Chiu TL; Pang CY
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):315-22. PubMed ID: 24042854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
